Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Daiki Ogawara"'
Autor:
Ou Yamaguchi, Norimitsu Kasahara, Hiroshi Soda, Hisao Imai, Ichiro Naruse, Hiroyuki Yamaguchi, Miki Itai, Kohei Taguchi, Megumi Uchida, Noriaki Sunaga, Toshitaka Maeno, Koichi Minato, Hiromi Tomono, Daiki Ogawara, Hiroshi Mukae, Yu Miura, Ayako Shiono, Atsuto Mouri, Hiroshi Kagamu, Kyoichi Kaira
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Circulating tumor DNA (ctDNA) provides molecular information on tumor heterogeneity. The prognostic usefulness of ctDNA after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are limited. Therefore, the pr
Externí odkaz:
https://doaj.org/article/136751bf535d4857a7d70d282fd7c6bf
Autor:
Shinnosuke Takemoto, Kazumasa Akagi, Sawana Ono, Hiromi Tomono, Noritaka Honda, Takayuki Suyama, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Daiki Ogawara, Hiroaki Senju, Hiroshi Gyotoku, Nanae Sugasaki, Hiroyuki Yamaguchi, Katsumi Nakatomi, Minoru Fukuda, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 12, Iss 17, Pp 2300-2306 (2021)
Abstract Background S‐1 and pemetrexed (PEM) are key treatments for non‐small cell lung cancer (NSCLC). However, the mechanism of anticancer activity of S‐1 and PEM is similar. Cross‐resistance between S‐1 and PEM is of concern. This explor
Externí odkaz:
https://doaj.org/article/602db2692a2a4097822cef7b5d6f304e
Autor:
Hirokazu Taniguchi, Hiroyuki Yamaguchi, Yosuke Dotsu, Midori Shimada, Hiroshi Gyotoku, Hiroaki Senju, Shinnosuke Takemoto, Takeshi Kitazaki, Masaaki Fukuda, Daiki Ogawara, Hiroshi Soda, Katsumi Nakatomi, Nanae Sugasaki, Akitoshi Kinoshita, Seiji Nagashima, Takaya Ikeda, Yoichi Nakamura, Noriho Sakamoto, Yasushi Obase, Minoru Fukuda, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 10, Iss 9, Pp 1764-1769 (2019)
Background The first‐line treatment for squamous cell lung cancer (SCC) has not necessarily been established; however, our previous exploratory study suggested that the combination of nedaplatin and amrubicin would be a promising treatment approach
Externí odkaz:
https://doaj.org/article/a4c5fc3cc43545d99dee8994a4d745d0
Autor:
Shinnosuke Takemoto, Yoichi Nakamura, Hiroshi Gyoutoku, Hiroaki Senju, Daiki Ogawara, Takaya Ikeda, Hiroyuki Yamaguchi, Takeshi Kitazaki, Hirofumi Nakano, Katsumi Nakatomi, Shinya Tomari, Shuntaro Sato, Seiji Nagashima, Minoru Fukuda, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 10, Iss 3, Pp 452-458 (2019)
Background We prospectively evaluated the efficacy and toxicity of a non‐platinum triplet regimen for patients with advanced non‐small cell lung cancer (NSCLC) expected to be platinum‐resistant. Methods Patients were diagnosed with NSCLC using
Externí odkaz:
https://doaj.org/article/2b3fae3714c2483aa51b824458e6380a
Autor:
Hiroshi Soda, Daiki Ogawara, Yuichi Fukuda, Hiromi Tomono, Daisuke Okuno, Seiko Koga, Hirokazu Taniguchi, Masataka Yoshida, Tatsuhiko Harada, Asuka Umemura, Hiroyuki Yamaguchi, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 10, Iss 2, Pp 341-346 (2019)
Several recent studies have shown that salvage chemotherapy following PD‐1 blockade produces high antitumor activity in some patients with non‐small lung cancer (NSCLC). However, the underlying synergistic mechanisms remain uncertain. The blood n
Externí odkaz:
https://doaj.org/article/dc34167674d345cd866b2e3e56886d39
Autor:
Tomoyuki Kakugawa, Kazuhiro Tabata, Daiki Ogawara, Tomoshi Tsuchiya, Shintaro Hara, Noriho Sakamoto, Yuji Ishimatsu, Kazuto Ashizawa, Takeshi Nagayasu, Junya Fukuoka, Shigeru Kohno
Publikováno v:
Respiratory Medicine Case Reports, Vol 13, Iss C, Pp 19-23 (2014)
In 2008, Kawabata et al. described a lesion which they termed “airspace enlargement with fibrosis” that could be included on the spectrum of smoking-related interstitial lung diseases. This group also reported that patients with airspace enlargem
Externí odkaz:
https://doaj.org/article/312e366e04614710a953fe9f1cae1d24
Publikováno v:
Cancer Management and Research, Vol 2010, Iss default, Pp 191-195 (2010)
Daiki Ogawara1, Minoru Fukuda2, Yoichi Nakamura3, Shigeru Kohno31Department of Medicine, Sasebo Central Hospital, 2Department of Medicine, Nagasaki Municipal Hospital, 3Second Department of Internal Medicine, Nagasaki University School of Medicine, N
Externí odkaz:
https://doaj.org/article/e6147382c8d2406ab4a69ac37b36ec49
Autor:
Hiroshi Mukae, Noritaka Honda, Nanae Sugasaki, Hiromi Tomono, Shinnosuke Takemoto, Yasuhiro Umeyama, Hiroyuki Yamaguchi, Sawana Ono, Daiki Ogawara, Katsumi Nakatomi, Hiroaki Senju, Kazumasa Akagi, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyotoku, Takayuki Suyama, Minoru Fukuda
Publikováno v:
Thoracic Cancer
Thoracic Cancer, Vol 12, Iss 17, Pp 2300-2306 (2021)
Thoracic Cancer, Vol 12, Iss 17, Pp 2300-2306 (2021)
Background S‐1 and pemetrexed (PEM) are key treatments for non‐small cell lung cancer (NSCLC). However, the mechanism of anticancer activity of S‐1 and PEM is similar. Cross‐resistance between S‐1 and PEM is of concern. This exploratory stu
Autor:
Ou Yamaguchi, Norimitsu Kasahara, Hiroshi Soda, Hisao Imai, Ichiro Naruse, Hiroyuki Yamaguchi, Miki Itai, Kohei Taguchi, Megumi Uchida, Noriaki Sunaga, Toshiaki Maeno, Koichi Minato, Hiromi Tomono, Daiki Ogawara, Hiroshi Mukae, Yu Miura, Ayako Shiono, Atsuto Mouri, Hiroshi Kagamu, Kyoichi Kaira
Background: Circulating tumor DNA (ctDNA) provides molecular information on tumor heterogeneity. Data regarding the predictive significance of ctDNA after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are limite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d009bcac70dcbc29f73657475864bbe3
https://doi.org/10.21203/rs.3.rs-1517908/v1
https://doi.org/10.21203/rs.3.rs-1517908/v1
Autor:
Takaya Ikeda, Katsumi Nakatomi, Akitoshi Kinoshita, Nanae Sugasaki, Hiroshi Gyotoku, Yosuke Dotsu, Noriho Sakamoto, Seiji Nagashima, Daiki Ogawara, Midori Shimada, Yasushi Obase, Hiroaki Senju, Hirokazu Taniguchi, Yoichi Nakamura, Masaaki Fukuda, Takeshi Kitazaki, Minoru Fukuda, Hiroshi Mukae, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Hiroshi Soda
Publikováno v:
Thoracic Cancer, Vol 10, Iss 9, Pp 1764-1769 (2019)
Thoracic Cancer
Thoracic Cancer
BACKGROUND The first-line treatment for squamous cell lung cancer (SCC) has not necessarily been established; however, our previous exploratory study suggested that the combination of nedaplatin and amrubicin would be a promising treatment approach f